Incyte Corporation
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
(855) 446-2983Website: https://www.incyte.com/Careers: https://www.incyte.com/join-us...Patient Assistance Program: https://www.incytecares.com
Latest News
- Incyte Announces FDA Approval of Jakafi (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) - September 22, 2021
- FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) - September 21, 2021
- Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis - June 11, 2021
- Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo - May 17, 2021
- Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis - February 19, 2021
- FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma - April 17, 2020
- Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis - January 28, 2020
- Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements - December 1, 2019
- Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma - November 27, 2019
- Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma - October 21, 2019
Drugs Associated with Incyte Corporation
Incyte Corporation manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Jakafi
Generic name: ruxolitinib Drug class: multikinase inhibitors |
18 reviews | 6.2 / 10 |
|
Opzelura
Generic name: ruxolitinib Drug class: topical antineoplastics |
||
|
Pemazyre
Generic name: pemigatinib Drug class: multikinase inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||